Provided by Tiger Trade Technology Pte. Ltd.

Johnson & Johnson

266.35
-0.7300-0.27%
Pre-market: 267.300.9500+0.36%07:40 EDT
Volume:4.93M
Turnover:1.32B
Market Cap:641.72B
PE:30.84
High:271.27
Open:270.21
Low:265.72
Close:267.08
52wk High:281.07
52wk Low:173.33
Shares:2.41B
Float Shares:2.40B
Volume Ratio:0.76
T/O Rate:0.21%
Dividend:5.24
Dividend Rate:1.97%
EPS(TTM):8.64
EPS(LYR):11.03
ROE:25.74%
ROA:8.59%
PB:7.55
PE(LYR):24.14

Loading ...

24H | Celestica Jumps 8%; Applied Digital, Cadence Rise 4%; Memory Chip and Crypto Stocks Drop

US Overnight
·
Jul 28

Johnson & Johnson Announces $5.5 Billion Settlement of Talc Lawsuits

Reuters
·
Jul 28

J&J announces proposed resolution of ovarian talc litigation

TIPRANKS
·
Jul 28

Movement Alert|Johnson & Johnson Rises 5.28% in After-Hours Trading, OTTAVA Robotic Surgical System Receives FDA Authorization

Market Focus
·
Jul 28

Johnson & Johnson Reaches Proposed $5.5 Billion Deal to Resolve Ovarian Talc Lawsuits

Reuters
·
Jul 28

Johnson & Johnson Announces a Proposed Resolution of Ovarian Talc Litigation

THOMSON REUTERS
·
Jul 28

J&J - Mdl Court Ordered Plaintiffs to Justify Remaining Talc Claims on July 22, 2026

THOMSON REUTERS
·
Jul 28

J&J: First Payment of no More than $3 Billion to Talc Litigation Resolution to be Made in 2027 and no Additional Payments Due Before 2028

THOMSON REUTERS
·
Jul 28

J&J: Studies Show Talc is Safe, Does not Contain Asbestos and Does not Cause Cancer

THOMSON REUTERS
·
Jul 28

J&J: the Proposed Resolution Constitutes Efficient Conclusion to the Talc Litigation - Website

THOMSON REUTERS
·
Jul 28

J&J Innovation Launches Intratumoral Cancer Treatments Quickfire Challenge

Reuters
·
Jul 27

Insiders Shake Up TSMC, Johnson & Johnson, Strategy, Snap, 3M

TIPRANKS
·
Jul 25

Does Illinois Talc Verdict Successor Liability Ruling Change The Bull Case For Kenvue (KVUE)?

Simply Wall St.
·
Jul 24

Ema's Chmp: Recommends Granting Marketing Authorisation for Icotyde

THOMSON REUTERS
·
Jul 24

J&J Names C1do1, Curium Life Tech, Iq Surgical as Polyphonic AI Fund for Surgery Cohort at SRS Meeting

Reuters
·
Jul 23

J&J Says In-development Blood Cancer Treatment Can Reduce Risk of Death, Disease Progression

Dow Jones
·
Jul 23

Johnson & Johnson's Tecvayli, Talvey Phase 3 Study in Relapsed or Refractory Multiple Myeloma Improves Progression-Free Survival

MT Newswires Live
·
Jul 23

Johnson & Johnson Posts Press Release on Monumental-6 Multiple Myeloma Trial Results

Reuters
·
Jul 23

J&J - Monumental-6 Shows Significant Improvements in Progression-free and Overall Survival Versus Standard of Care

THOMSON REUTERS
·
Jul 23

Tecvayli® + Talvey® Reduced the Risk of Disease Progression or Death by 89% and the Risk of Death by 62% in Earlier-line Relapsed/refractory Multiple Myeloma

THOMSON REUTERS
·
Jul 23